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In recent years, lipids have come to the foreground as signaling mediators in the central nervous system (CNS)1,2. While classi-cal neurotransmitters are stored in synaptic vesicles and released 
on fusion with the plasma membrane of neurons, due to their lipo-
philic nature, lipids readily diffuse through membranes and are not 
stored in vesicles. It is, therefore, generally accepted that signaling 
lipids are produced ‘on demand’ and are rapidly metabolized to 
terminate their biological action3. In particular, NAEs, including 
N-palmitoylethanolamine (PEA), N-oleoylethanolamine (OEA) and 
the endocannabinoid anandamide (N-arachidonoylethanolamine, 
AEA) have emerged as key lipid signaling molecules. Genetic dele-
tion or pharmacological inhibition of the main NAE hydrolytic 
enzyme, fatty acid amide hydrolase (FAAH), revealed elevated 
anandamide, PEA and OEA levels in brain and implicated these 
molecules in the modulation of various physiological processes 
such as pain, stress, anxiety, appetite, cardiovascular function and 
inflammation4–7. The physiological effects resulting from pertur-
bation of the production of anandamide and other NAEs in living 
systems are, however, poorly studied, partly because of a lack of 
pharmacological tools to modulate their biosynthetic enzymes8.
NAPE-PLD is generally considered a principal NAE bio-
synthetic enzyme9,10. Biochemical and structural studies have 
demonstrated that NAPE-PLD is a membrane-associated, consti-
tutively active zinc hydrolase with a metallo-β-lactamase fold11. 
The enzyme generates a broad range of NAEs by hydrolysis of the 
phosphodiester bond between the phosphoglyceride and the NAE 
in N-acylphosphatidylethanolamines (NAPEs)12. Knockout (KO) 
studies have shown that the Ca2+-dependent conversion of NAPE 
to NAEs bearing both saturated and polyunsaturated fatty acyl 
groups are fivefold reduced in brain lysates from mice that geneti-
cally lack Napepld13. In accordance, reduced levels of saturated and 
mono-unsaturated NAEs were observed in the brains of NAPE-PLD 
KO mice13–15. Anandamide levels were not reduced in the trans-
genic model reported by Leung et al., which suggested the presence 
of compensatory mechanisms13. Indeed, multiple alternative bio-
synthetic pathways for anandamide have been discovered since10. 
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N-acylethanolamines (NAEs), which include the endocannabinoid anandamide, represent an important family of signaling 
lipids in the brain. The lack of chemical probes that modulate NAE biosynthesis in living systems hamper the understanding 
of the biological role of these lipids. Using a high-throughput screen, chemical proteomics and targeted lipidomics, we report here 
the discovery and characterization of LEI-401 as a CNS-active N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) 
inhibitor. LEI-401 reduced NAE levels in neuroblastoma cells and in the brain of freely moving mice, but not in NAPE-PLD KO 
cells and mice, respectively. LEI-401 activated the hypothalamus–pituitary–adrenal axis and impaired fear extinction, thereby 
emulating the effect of a cannabinoid CB1 receptor antagonist, which could be reversed by a fatty acid amide hydrolase inhibi-
tor. Our findings highlight the distinctive role of NAPE-PLD in NAE biosynthesis in the brain and suggest the presence of an 
endogenous NAE tone controlling emotional behavior.
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Of note, two other NAPE-PLD KO strains have been generated, which 
did show a decreased brain anandamide content14,15. Constitutive 
genetic mouse models are, however, poorly suited to study the rapid 
and dynamic formation of NAEs and their biological functions. 
Potent CNS-active inhibitors of NAPE-PLD are currently not avail-
able. Previously described NAPE-PLD inhibitors lack the potency, 
selectivity and/or physicochemical properties to study the role of this 
enzyme in in vivo systems in an acute setting16–18. Thus, a need exists 
for pharmacological tools that inhibit NAE biosynthesis in the brain.
Here, we report the discovery of LEI-401 (1) as a brain active 
NAPE-PLD inhibitor. High-throughput screening (HTS) and a 
medicinal chemistry program led to the identification of LEI-401 
as a potent and selective NAPE-PLD inhibitor. LEI-401 reduced a 
broad range of NAEs including anandamide in neuronal cells in a 
NAPE-PLD-dependent manner. Anandamide and other NAE levels 
were reduced in the brain of wild-type (WT) mice treated with LEI-
401, but not in NAPE-PLD KO mice. The compound activated the 
hypothalamus–pituitary–adrenal (HPA) axis and impaired extinc-
tion of an aversive memory in mice, thereby mimicking the effects 
of cannabinoid CB1 receptor antagonism. These behavioral effects 
were prevented by a FAAH inhibitor. Taken together, LEI-401 is 
a first-in-class brain active NAPE-PLD inhibitor that blocks NAE 
biosynthesis in the brain of freely moving mice, thereby revealing a 
possible endogenous tone of this lipid family in emotional behavior.
Results
New NAPE-PLD inhibitor chemotypes are identified by HTS. To 
identify new inhibitors for NAPE-PLD, we initiated a HTS campaign 
in collaboration with the European Lead Factory (Supplementary 
Table 1)19. A previously reported fluorescent NAPE-PLD activity 
assay20 using the surrogate substrate N-((6-(2,4-dinitrophenyl)
amino)hexanoyl)-2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a- 
diaza-s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-p
hosphoethanol-amine triethylammonium salt (PED6) was converted 
to a HTS-compatible 1,536-well format (Fig. 1a). As an enzyme 
source, we used membrane fractions of human embryonic kidney 
293T (HEK293T) cells that were transiently transfected with human 
NAPE-PLD (Supplementary Fig. 1). This resulted in a robust assay 
with a Z’ = 0.87, a signal-to-background ratio of 6.7 and intraplate 
variability (coefficient of variability) of <3.3%. Approximately 350,000 
compounds were screened at a single concentration (10 μM) in 294 
plates over 3 d, affording 8,321 actives (using the cut-off value of Z 
score ≤ −7) (Fig. 1b,c). Hit validation at the same concentration yielded 
3,885 confirmed actives. To reduce the number of compounds, the 
percentage effect on the enzyme activity (≥40%) was used to obtain 
a list of 1,120 actives. Next, dose-response curves were generated in 
the presence and absence of ZnSO4 (100 μM) to remove promiscuous 
Zn2+-ion chelators, which yielded 352 hits. Visual inspection of the 
352 compounds revealed the presence of potential assay interfering 
compounds that absorbed light within the visible wavelength; there-
fore, a second deselection assay was developed. The substrate PED6 
was incubated with lysate to obtain the maximum fluorescent signal, 
followed by incubation with different concentrations of the confirmed 
actives to determine the ability of the compounds to quench the 
fluorescent signal under the primary assay conditions. Compounds 
demonstrating no effect (half-maximal inhibitory concentration with 
negative log (pIC50) < 5) in the second deselection assay were selected 
(Supplementary Table 2). The compounds were checked for purity 
(>85%) and correct molecular weight by liquid chromatography–
mass spectrometry (LC–MS) analysis. This afforded a qualified hit list 
of five compounds (2–6) with four different chemotypes (Fig. 1d).
Hit optimization provides nanomolar inhibitor LEI-401. 
Compound 2 (N-(cyclopropylmethyl)-2-(methyl(phenethyl)amino)- 
6-morpholinopyrimidine-4-carbox-amide) displayed the most opti-
mal biological and physicochemical characteristics (molecular weight 
of 396 Da, calculated partition coefficient c-logP = 3.84) (Fig. 1d  
and Supplementary Table 2). On resynthesis, chemical analysis and 
retesting, the identity and submicromolar activity (Ki = 0.30 μM, 
95% CI = 0.22–0.38 μM) of the hit was confirmed (Fig. 2 and 
Supplementary Notes). To improve the inhibitory activity of com-
pound 2, a medicinal chemistry program was initiated in which 112 
derivatives were synthesized. A full report of the medicinal chemistry 
program will be described elsewhere; however, in brief, we discov-
ered that replacing the morpholine for a (S)-3-hydroxypyrrolidine 
(7) improved activity (Ki = 0.086 μM, 95% CI, 0.058–0.14 μM), 
while simultaneously decreasing lipophilicity (c-logP = 3.46) 
(Fig. 2a,b). The absolute configuration of the hydroxyl was not 
essential for binding, as the (R)-enantiomer 8 showed similar 
potency (Ki = 0.11 μM, 95% CI, 0.096–0.13 μM). Conformational 
restriction of the phenethylamine moiety to a (S)-3-phenylpiperidine 
(1) further increased the potency (Ki = 0.027 μM, 95% CI, 0.021–
0.033 μM), whereas its (R)-enantiomer 9 was three times less active 
(Ki = 0.094 μM, 95% CI, 0.071–0.12 μM) (Fig. 2b). In view of the bio-
logical activity profile, we decided to further characterize compound 
1 (termed LEI-401).
To profile NAPE-PLD inhibitors in mouse models, we assessed 
whether LEI-401 showed any species difference using recombi-
nant mouse NAPE-PLD expressed in HEK293T cells. LEI-401 
retained activity on mouse NAPE-PLD in the PED6 assay, albeit at a 
reduced potency (Ki = 0.18 μM, 95% CI, 0.15–0.21 μM). Next, we 
investigated the activity of LEI-401 on NAPE-PLD in a secondary 
in vitro assay to confirm an on-target effect of the inhibitor. To this 
end, we measured the NAPE-PLD enzyme activity in brain lysates of 
WT and NAPE-PLD KO mice by quantifying the formation of NAE 
(C17:0) from a synthetic C17:0-NAPE using an LC–MS-based assay21. 
LEI-401 reduced C17:0-NAE formation using brain homogenates of 
WT mice, but not from KO mice (Supplementary Fig. 3), thereby con-
firming that NAPE hydrolysis and its inhibition by LEI-401 in ex vivo 
preparations is dependent on NAPE-PLD in mouse brain. Following 
this, we assessed the activity profile of LEI-401 for the receptors and 
metabolic enzymes of the endocannabinoid system. No inhibitory 
activities were measured at 10 μM for the cannabinoid receptors type 
1 and type 2 (Supplementary Table 3) as well as for the other enzymes 
involved in anandamide biosynthesis and degradation, such as phos-
pholipase A2 group 4E (PLA2G4E) and FAAH (Supplementary 
Table 4), respectively. In addition, LEI-401 did not inhibit enzymes 
involved in the biosynthesis and degradation of the other endocan-
nabinoid 2-arachidonoylglycerol (2-AG), including diacylglycerol 
lipases (DAGLα or DAGLβ), monoacylglycerol lipase (MAGL) and 
α,β-hydrolase domain 6 (ABHD6) (Supplementary Table 4).
Photoaffinity labeling shows NAPE-PLD target engagement. To 
assess target engagement and selectivity of LEI-401 in cellular sys-
tems, we turned to a photoaffinity labeling approach, which was pre-
viously successfully applied for other metallo-enzymes22. Based on 
the structure-activity relationships of LEI-401, a photoactivatable 
alkyne probe (10) was synthesized in which the 3-phenyl-piperidine 
was replaced with a trifluoromethyl-diazirine-benzyl-piperazine as 
a photoreactive group (Fig. 3a and Supplementary Notes). In addi-
tion, the methylcyclopropyl group was substituted for a propargyl 
group to serve as a ligation handle to introduce reporter groups 
by copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC, 
or ‘click’) chemistry to study target engagement. First, we con-
firmed that compound 10 inhibited NAPE-PLD with a Ki of 
0.18 μM (95% CI, 0.11–0.27 μM) in the biochemical PED6-assay 
(Supplementary Fig. 4). To assess whether compound 10 was able 
to visualize NAPE-PLD, HEK293T cells were transfected with 
hNAPE-PLD-FLAG or control (mock) plasmid for 48 h, followed 
by in situ treatment with compound 10 (2 μM) for 30 min and then 
irradiated at 350 nm for 10 min. After lysis and clicking of a Cy5-N3 
fluorophore, the samples were resolved by SDS-polyacrylamide gel 
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electrophoresis (SDS–PAGE) and protein labeling was visualized 
by in-gel fluorescence scanning (Supplementary Fig. 5–7). An addi-
tional band at the expected molecular weight of ~46 kDa was appar-
ent in the hNAPE-PLD-transfected cells but not in mock-treated 
cells, at the same height as the signal of an anti-FLAG antibody 
on western blot (Fig. 3b). The intensity of the fluorescent band 
at 46 kDa was reduced on coincubation by the inhibitor LEI-401 
(Fig. 3b), indicating that LEI-401 bound to NAPE-PLD in living 
cells. Concentration-response experiments revealed that LEI-401 
dose-dependently reduced the labeling of NAPE-PLD with an IC50 
of 0.86 μM (95% CI, 0.60–1.2 μM) (Fig. 3c,d). To establish the selec-
tivity of LEI-401, a label-free chemical proteomics experiment was 
performed23. Cell lysates prepared from hNAPE-PLD-transfected 
HEK293T cells incubated with photoprobe 10 were clicked with 
biotin-N3, which allowed for enrichment of probe-labeled pro-
teins using avidin agarose beads, followed by trypsin digestion and 
protein identification by mass spectrometry. Proteomic analysis 
allowed identification of 136 proteins (Fig. 3e). NAPE-PLD was 
enriched by probe 10 in an ultraviolet (UV)-dependent manner 
and its labeling could be prevented by coincubation with LEI-401 
(Fig. 3f). Furthermore, LEI-401 did not compete for other pro-
tein targets of probe 10 in this analysis or in mock-transfected 
HEK293T cells (Fig. 3f and Supplementary Fig. 8). In summary, 
the development of photoaffinity probe 10 enabled the detection 
of NAPE-PLD in living cells and visualization of target engagement 
by LEI-401 with NAPE-PLD.
LEI-401 lowers NAEs in WT but not in NAPE-PLD KO cells. 
Having established that LEI-401 is a cell-permeable inhibitor and 
engages with NAPE-PLD, we then investigated whether LEI-401 
inhibited endogenous NAPE-PLD in living cells. To this end, the 
mouse Neuro-2a neuroblastoma cell line was selected, since it 
expressed endogenous NAPE-PLD as determined by quantita-
tive PCR (qPCR; Supplementary Table 5) and western blot using 
NAPE-PLD antibodies (Supplementary Fig. 9). Targeted lipidomics 
on lipid extracts of Neuro-2a cells allowed the quantification of 
eight different NAEs by LC–MS (Fig. 4a). As an appropriate nega-
tive control, two NAPE-PLD KO cell lines were generated using 
CRISPR/Cas9. The cell line KO-2 showed more efficient ablation 
of NAPE-PLD protein expression as demonstrated by western blot 
analysis compared to KO-1 and was therefore chosen for further anal-
ysis (Supplementary Fig. 9). Next, we incubated both WT and KO 
cells with LEI-401 (10 μM) for 2 h. A significant twofold reduction 






























































































































Fig. 1 | HTS of a NAPE-PLD activity assay provided potent new inhibitors 2–6. a, Cleavage of PeD6 generated a fluorescent read-out of NAPe-PLD 
activity. b, Primary activity screen. c, Hit triage of the HTS campaign. d, Structures, potency data and physicochemical parameters of hit compounds 
(2–6). Data represent mean values ± s.e.m. for two independent experiments with two biological replicates (n = 4). Dose-response curves are depicted in 
Supplementary Fig. 2. Complete HTS data are listed in Supplementary Tables 1 and 2.
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cells, indicating that the LEI-401-induced reduction in anandamide 
levels depended on expression of NAPE-PLD in Neuro-2a cells 
(Fig. 4b). LEI-401-treated cells did not show any sign of reduced cell 
viability (Supplementary Fig. 10). It is worth noting that the smaller 
but significant decrease of anandamide (~25%) in NAPE-PLD KO 
cells compared to WT may indicate the occurrence of compensa-
tory mechanisms in the knockout cells, as also observed by others 
in Napepld-deficient mice (Supplementary Fig. 11a)13. Furthermore, 
other saturated, mono- and (ω-6)-polyunsaturated NAEs showed a 
similar twofold decrease in WT cells on LEI-401 pretreatment, but 
not in NAPE-PLD KO cells (Fig. 4b and Supplementary Fig. 11b–f). 
Of note, (ω-3)-polyunsaturated N-eicosapentanoylethanolamine 
(EPEA) and N-docosahexanoylethanolamine (DHEA) and did not 
respond to LEI-401 treatment (Fig. 4b and Supplementary Fig. 11g,h). 
Our data are in line with previously reported biochemical substrate 
studies using purified recombinant NAPE-PLD12 and indicate that 
endogenously expressed NAPE-PLD is responsible for biosynthesis 
of saturated, mono- and (ω-6)-polyunsaturated NAEs in Neuro-2a 
cells. The lack of effect on (ω-3)-polyunsaturated NAEs may sug-
gest that these signaling lipids are produced via another pathway. 
Of note, recently it was found that dietary (ω-3)-polyunsaturated 
fatty acids augment NAE levels in mice via a pathway independent 
of NAPE-PLD24.
LEI-401 is brain-penetrant and reduces brain NAE levels. To 
assess whether LEI-401 possesses in  vivo efficacy, we first deter-
mined its in vitro absorption, distribution, metabolism and excretion 
(ADME) profile. LEI-401 demonstrated favorable physicochemical 
properties for oral bioavailability and brain penetration (molecular 
weight of 422 Da; logD = 3.3 and topological polar surface area of 
80.5 Å2). LEI-401 had low aqueous solubility (1.7 mg l−1) and perme-
ates well through membranes (parallel artificial membrane perme-
ability assay (PAMPA) Peff = 0.37 nm s−1). Clearance in human and 
mouse microsomes (10 and 42 μl min−1 mg−1 protein, respectively) 
as well as in human and mouse hepatocytes (6.9 and 28.8 μl min−1 
per 106 cells, respectively) was moderate, except for the low human 
microsomal clearance. LEI-401 exhibited high human and mouse 
protein binding of >99.8%. It is worth noting that it did not interact 
with either human or mouse PGP-transporter (efflux ratios were 1.7 
and 1.8, respectively).
Pharmacokinetic analysis in male C57BL/6J mice revealed a low 
clearance (CL = 5.2 ml min−1 kg−1) and moderate volume of distri-
bution (Vss = 1.2 l kg−1), resulting in a half-life of 2.7 h (Fig. 5a and 
Supplementary Table 6). The low in vivo clearance was unexpected 
based on the in vitro clearance, but could be explained by the tight 
protein binding. Bioavailability after oral administration reached 
25% and a more favorable bioavailability was achieved via intra-
peritoneal (i.p.) injection (Fip = 48%). In both cases, good plasma 
exposures were obtained. The brain to plasma ratio was 0.7 at Cmax  
(2 h postinjection). This led to an excellent brain exposure (>10 μM) 
after 30 mg kg−1 i.p. administration (Fig. 5b), which corresponds to 
approximately 70-fold the mouse NAPE-PLD Ki-value, and should 
be sufficient to modulate NAPE-PLD activity in mouse brain.
In view of the encouraging pharmacokinetic properties and brain 
exposure, we administered LEI-401 or vehicle to male C57BL/6J 
mice (30 mg kg−1, i.p., single dose) and killed the mice after 1, 2, 4 or 
8 h to determine whether NAE levels were reduced. To this end, we 
analyzed brain NAE levels by LC–MS. LEI-401 induced a significant 
and time-dependent reduction for anandamide (P = 0.0051), which 
was significant at 2 h and returned to vehicle level by 4 h (Fig. 5c). 
A similar trend, although not significant, was observed for OEA and 
DHEA (Supplementary Fig. 12a,b). Next, mice were treated with 
various doses of LEI-401 (3, 10 and 30 mg kg−1 or vehicle, i.p., single 
dose) and brain lipids were analyzed at 2 h. LEI-401 (30 mg kg−1) 
significantly reduced anandamide (Fig. 5d). Other NAE lipid 













































































Fig. 2 | Hit optimization affords nanomolar potent inhibitor LEI-401. a, Respective substitution of the morpholine and N-methylphenethylamine of 2 
for a (S)-3-hydroxypyrrolidine and (S)-3-phenylpiperidine provided LeI-401. b, hNAPe-PLD in vitro activity assay dose-response curves for inhibitors 1 
(Ki = 0.027 μM, 95% CI 0.021–0.033 μM), 2 (Ki = 0.30 μM, 95% CI 0.22–0.38 μM), 7 (Ki = 0.086 μM, 95% CI 0.058–0.14 μM), 8 (Ki = 0.11 μM, 95% CI 
0.096–0.13 μM) and 9 (Ki = 0.094 μM, 95% CI 0.071–0.12 μM). Data represent mean values ± s.e.m. for two independent experiments with two biological 
replicates (n = 4).
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The 2-AG levels were not significantly affected by LEI-401 treat-
ment (30 mg kg−1, i.p.) (Supplementary Figs. 12c and 13d). In 
line, the activity of the 2-AG producing and degrading enzymes 
DAGLα/β, MAGL and ABHD6 in the brain was not affected 
(Supplementary Fig. 14). LEI-401 did not reduce brain NAE lev-
els in NAPE-PLD KO mice (Supplementary Fig. 15a–c,f–h), which 
indicated that LEI-401 is a selective NAPE-PLD inhibitor. Of note, 
we found that anandamide levels were not decreased by LEI-401 
in WT littermates of the NAPE-PLD KO animals, which originate 
from a mixed 129SvJ-C57BL/6 background, while PEA and OEA 
levels were significantly reduced (Supplementary Fig. 15f–h). This 
is in line with previous genetic studies using animals from the same 
background13. Furthermore, 2-AG levels were increased in KO 
mice at a dose of 60 mg kg−1, whereas AA levels were decreased at 
this dose in animals of both genotypes (Supplementary Fig 15i,j). 
This indicated that at this high dose LEI-401 has an off-target that 
modulates 2-AG and AA levels. To determine whether acute inhibi-
tion of NAPE-PLD would affect its substrate levels, we determined 
NAPE and plasmalogen NAPE (pNAPE) levels in the brain of LEI-
401-treated mice. No change in NAPE or pNAPE species was found 
for LEI-401 compared to vehicle in both WT and NAPE-PLD KO 
mice (Supplementary Figs. 16 and 17). Collectively, these data indi-
cate that LEI-401 is an in vivo active NAPE-PLD inhibitor that can 
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Fig. 3 | Photoprobe 10 visualizes target engagement of LEI-401 with NAPE-PLD in situ. a, Structure of NAPe-PLD photoprobe 10. b, Fluorescent labeling 
of hNAPe-PLD-FLAG at ~46 kDa in overexpressing HeK293T cells (middle lane) but not in mock-transfected cells (left lane) with photoprobe 10 (2 μM, 
30 min). The NAPe-PLD band was competed out by LeI-401 (20 μM, 30 min coincubation) (right lane). Anti-FLAG western blot displays hNAPe-PLD-FLAG 
expression. M, mock; N, hNAPe-PLD-FLAG. Representative gel of three biologically independent experiments (n = 3). c, Dose-dependent competition of 
photoprobe 10 (2 μM) with LeI-401 (30 min coincubation). Representative gel of three biologically independent experiments (n = 3). For b,c, Coomassie 
or α-tubulin was used as a loading control. See Supplementary Figs. 6 and 7 for full gels and blots. d, Dose-response curve of LeI-401 with 95% CI 
(dotted lines); IC50 = 0.86 μM (95% CI, 0.60–1.2 μM). Data represent mean values ± s.e.m. for three biological replicates (n = 3). e, Waterfall plot showing 
UV-enriched protein targets of photoprobe 10 in hNAPe-PLD-FLAG-transfected HeK293T cells (three biological replicates per condition (n = 3)).  
f, Volcano plot displaying competed protein targets for photoprobe 10 (2 μM) versus LeI-401 (20 μM) in hNAPe-PLD-FLAG-transfected HeK293T cells 
(three biological replicates per condition (n = 3)). Cut-off values used for e,f: unique peptides ≥2; log2(fold change) ≥ 1 (for e, ratio +UV/−UV intensity 
probe 10 and for f, ratio photoprobe 10 intensity/LeI-401 intensity), P < 0.05 using Student’s t-test (unpaired, two-tailed) and Benjamini–Hochberg 
correction (10% FDR).
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LEI-401 modulates emotional behavior. NAEs are implicated in 
the regulation of emotional behavior, such as acute stress responses, 
anxiety and fear extinction6,25,26. It is hypothesized that a basal tone 
of anandamide, acting via the cannabinoid CB1 receptor, constrains 
activation of the HPA axis and controls the extinction of aversive 
memories5. This hypothesis is supported by experiments in which 
anandamide levels were elevated via pharmacological and genetic 
modulation of FAAH or by blocking the cannabinoid CB1 recep-
tor27–33. More so, stress exposure itself is known to reduce anan-
damide levels in vivo and reversal of this suppression of anandamide 
signaling, via inhibition of FAAH, is known to counter many effects 
of stress such as activation of the HPA axis and alterations in anxi-
ety34–36. Direct evidence that reducing NAE levels by pharmaco-
logical tools will affect emotional behavior has, however, not been 
obtained yet. LEI-401 is the first chemical probe that allows us to 
test this hypothesis. To this end, we first measured c-Fos protein 
expression in the paraventricular nucleus (PVN) of the hypothala-
mus, a primary integratory site for the HPA axis and a nucleus that 
is reliably activated by stress exposure, and determined circulating 
corticosterone (CORT) levels in mice 2.5 h after administration of 
LEI-401 (30 mg kg−1, i.p., single dose), a CB1 receptor antagonist 
(AM251, 3 mg kg−1, i.p., single dose) or vehicle. PVN brain sections 
revealed that LEI-401 (P < 0.0001) and AM251 (P = 0.011) elevated 
c-Fos protein expression (Fig. 6a–d and Supplementary Fig. 18a–c). 
Notably, the effect of LEI-401 was reversed by cotreatment with 
the FAAH inhibitor URB597 (i.p., 1 mg kg−1, single dose; P = 0.016) 
(Fig. 6c,d). Plasma CORT levels were significantly higher in LEI-
401-treated mice compared to control (P = 0.047), but not when 
cotreated with a FAAH inhibitor (P = 0.0027) (Fig. 6e). Similarly, 
an increase in plasma CORT was also observed for AM251-treated 
mice (P = 0.0042; Supplementary Fig. 18d). These data suggest that 
NAPE-PLD provides a basal NAE tone, which restricts the activa-
tion of the HPA axis.
Next, to determine the consequences of depleting the endoge-
nous NAE tone on a measure of emotional behavior, we tested LEI-
401 on mouse fear extinction37. First, C57BL/6J mice were trained 
to fear (quantified as freezing ‘no movement else than breathing’ 
levels) an auditory conditioned stimulus by repeated pairings with 
an unconditioned stimulus (US, footshock). One day after con-
ditioning, mice were treated with LEI-401 (i.p., 30 mg kg−1, single 
dose), LEI-401 cotreatment with a FAAH inhibitor (AM3506, i.p., 
1 mg kg−1, single dose) or vehicle 1 h and 45 min before a fear extinc-
tion training involving 50× conditioned stimulus presentations. A 







































































































































































































Fig. 4 | LEI-401 reduces NAE levels in Neuro-2a cells, but not in NAPE-PLD KO cells. a, Absolute NAe levels of Neuro-2a WT and NAPe-PLD KO cells.  
b, Relative NAe levels of Neuro-2a WT and NAPe-PLD KO cells treated with LeI-401 (10 μM, 2 h), represented as effect percentage. Data were normalized 
against WT or NAPe-PLD KO cells treated with vehicle (DMSO). Absolute values for all NAes are depicted in Supplementary Fig. 11. For a,b, data represent 
mean values ± s.e.m. for five biological replicates (n = 5). P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.
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extinction. This entailed 5× conditioned stimulus presentations 
(Supplementary Fig. 19). LEI-401 administration produced a sig-
nificant increase in freezing as compared to vehicle (P = 0.0099), 
which was reversed by coadministration of a FAAH inhibitor 
(Fig. 6f). These results reveal a key contribution of NAPE-PLD in 
mediating fear extinction.
Discussion
NAEs, including anandamide, PEA and OEA, have emerged as an 
important class of lipid signaling molecules that regulate various 
physiological and behavioral functions via multiple mechanisms, 
including G protein-coupled receptors (cannabinoid CB1 receptor, 
GPR110 and GPR119), ion channels (TRPV1 and TASK-1) and 
nuclear receptors (PPAR-α)38. Inhibitors of NAE degradation have 
shed light on the role of NAEs in pain39, satiety40 and inflammation41, 
and emotional states such as fear6, stress29 and anxiety27. However, 
assessing the biological consequences of NAE reductions represent 
an important challenge because of a lack of selective inhibitors that 
block in vivo NAE production.
Here, we have addressed these important questions by develop-
ing LEI-401 as a brain active inhibitor of NAPE-PLD, an enzyme 
responsible for NAE biosynthesis. HTS and a medicinal chemistry 
program led to the discovery of LEI-401 as a potent and selective 
NAPE-PLD inhibitor with good pharmacokinetic properties. Acute 
NAPE-PLD inhibition by LEI-401 in mouse neuronal Neuro-2a 
cells decreased saturated, mono- and (ω-6)-polyunsaturated NAEs 
(including anandamide), while leaving (ω-3)-polyunsaturated 
NAEs unperturbed. This effect was not present in Neuro-2a cells 
lacking NAPE-PLD, showing the specificity of LEI-401. Notably, 
acute NAPE-PLD inhibition resulted in lower anandamide levels 
than observed in the knockout cells, thereby indicating that 
long-term inactivation of NAPE-PLD in cells also may lead to 
activation of compensatory pathways (Supplementary Fig. 11a). 
LEI-401 reduced NAE formation from synthetic NAPE ex vivo 
using brain lysates from WT mice, but not from NAPE-PLD KO 
mice. Administration of LEI-401 to mice resulted in a significant 
decrease in anandamide, PEA and OEA content in the brain. The 
LEI-401-mediated reductions in NAEs were absent in NAPE-PLD 
KO mice, thereby indicating that LEI-401 is a selective NAPE-PLD 
inhibitor. Of note, we found that anandamide levels were acutely 
reduced by LEI-401 in C57BL/6J mice, but not in animals derived 
from a mixed 129SvJ-C57BL/6J background. These observations 
are consistent with previous studies using the same mouse strains, 
in which genetic ablation of NAPE-PLD in C57BL/6J mice resulted 
in reduced anandamide levels, but not in mice with a mixed back-
ground13,14. This reinforces the notion that besides NAPE-PLD 
alternative biosynthetic pathways exist for anandamide biosynthe-
sis, which not only become apparent after long-term inactivation 
of the Napepld gene10,13, but also appear to be functional in normal 
physiological conditions depending on the genetic context. While 
the molecular factors that govern the biosynthesis of anandamide 
in mice originating from a 129SvJ-C57BL/6J background remain 
unknown at this time, it cannot be excluded that NAPE-PLD regu-
lates anandamide biosynthesis in specific brain regions, cell types 
or other tissues in these mice. Regardless of the genetic context, 
our data indicate that LEI-401 is an in vivo active inhibitor that can 
be used to study the physiological role of NAPE-PLD. However, it 
should be noted that when studying the behavioral effects of LEI-
401 in relation to a reduction of anandamide levels it is important to 
take the genetic background of the animals into account.
LEI-401 provided us the opportunity to investigate the potential 
role of NAPE-PLD in emotional behavior. LEI-401 elicited a pro-
nounced activation of the HPA axis, which was mimicked by a CB1 
receptor antagonist and could be blocked by coadministration of a 
FAAH inhibitor. These findings support the hypothesis that a basal 
anandamide tone controls the activation of the HPA axis via the 
CB1 receptor5. LEI-401 also impaired fear extinction, an effect that 
was rescued by a FAAH inhibitor, consistent with previous findings 
in which genetic deletion or pharmacological blockade of the CB1 
receptor resulted in impaired fear extinction28,42–44. Taken together, 
our data are consistent with previous studies suggesting that anan-
damide may set an endogenous tone that plays a role in the neural 
circuitries mediating stress and fear behavior and provide experimen-
tal evidence that inhibition of NAPE-PLD is sufficient to modulate 
stress and fear. Whether the reduction of other NAEs, besides anan-
damide, also contribute to the observed behavioral effects of LEI-401 
cannot be excluded at the moment26. Taken together, our data lend 
further preclinical support to test FAAH inhibitors in the clinic for 
stress-related disorders, such as posttraumatic stress disorder, which 
has been reported to exhibit reduced levels of anandamide45,46.
Finally, our studies indicate that LEI-401 and photoreactive 
probe 10 constitute a valuable toolbox to study various aspects 
of NAPE-PLD and NAE biology both in animal and in cellular 
models. Although LEI-401 was selective in a chemical proteomics 
setting, did not inhibit DAGLα, DAGLβ, MAGL and ABHD6, and 
did not affect NAE, 2-AG and AA levels in NAPE-PLD KO mice at 
30 mg kg−1, it modulated brain 2-AG and AA levels at a higher dose 
of 60 mg kg−1 in both WT and KO mice. These observations indi-
cate that LEI-401 or its metabolites may have off-target activity and 
highlight the valuable role of combining chemical tools with genetic 
models to study on-target and off-target interactions of pharmaco-
logical agents. Second generation inhibitors will benefit from the 
identification of the off-targets. From a translational perspective, it 
will be interesting to study these inhibitors in various animal mod-
els of human disease, such as metabolic syndrome47, type II diabe-
tes48, neurodegeneration49, inflammatory and neuropathic pain50. 
The inhibitor reported in this study provided an opportunity 
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Fig. 5 | LEI-401 decreases AEA in mouse brain. a, In vivo pharmacokinetic 
profile of LeI-401 in plasma of C57BL/6J mice via intraperitoneal (i.p., 
30 mg kg−1), p.o. (10 mg kg−1) or i.v. (1 mg kg−1) administration. Data 
represent mean values ± s.e.m. n = 5 mice for time points 0.25 or 0.5 h, and 
n = 3 mice for 1, 2, 4 or 7 h. b, Brain pharmacokinetic profile of LeI-401 in 
C57BL/6J mice after i.p. administration (30 mg kg−1). c, Time-dependent 
effect of LeI-401 on brain AeA. C57BL/6J mice i.p. injected with LeI-
401 (30 mg kg−1). Veh, vehicle at 8 h. For b and c, data represent mean 
values ± s.e.m. with n = 5 mice for time points 1 or 2 h, and n = 4 mice for 
4 or 8 h. d, Dose-dependent effect of LeI-401 on brain AeA at 2 h after 
i.p. administration. Data represent mean values ± s.e.m. with n = 5 mice 
for dose groups 3 or 10 mg kg−1 and n = 11 mice for vehicle or 30 mg kg−1. 
P values were calculated using one-way ANOVA with Dunnett’s multiple 
comparisons test.
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to investigate NAE biosynthesis in the brain of living animals 
in an acute and dynamic manner, thereby revealing a possible 
endogenous tone of this lipid family in emotional behavior. 
It is envisioned that LEI-401 may help to validate NAPE-PLD as a 
therapeutic target and serve as a starting point for the discovery of 
future drug candidates.
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memory retrieval test 10 d after treatment with vehicle or LeI-401 (i.p., 30 mg kg−1, single dose). LeI-401-treated mice exhibited increased freezing versus 
vehicle, but not when coadministered with FAAH inhibitor AM3506 (i.p., 1 mg kg−1, single dose). Data represent mean values ± s.e.m. with n = 12 mice for 
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Methods
Cloning of plasmid DNA. Full length human cDNA of human or mouse 
NAPEPLD (obtained from N. Ueda9), hDAGLα, mDaglα, mDaglβ, hMAGL and 
hPLA2G4E was cloned into mammalian expression vector pcDNA3.1, containing 
a C-terminal FLAG-tag and genes for ampicillin and neomycin resistance. All 
plasmids were grown in XL-10 Z-competent cells and prepped (Maxi Prep, 
Qiagen). Constructs were verified by Sanger sequencing (Macrogen).
Cell culture. HEK293T or Neuro-2a cells (ATCC) were cultured at 37 °C and 7% 
CO2 in DMEM (Sigma Aldrich, D6546) with GlutaMax, penicillin (100 μg ml−1), 
streptomycin (100 μg ml−1) and 10% New Born Calf serum. Cells were passaged 
twice a week to appropriate confluence by thorough pipetting.
Transient transfection. One day before transfection, 107 cells were seeded on 
a 15 cm dish, and 2 h before transfection, the medium was refreshed with 13 ml 
medium. Transfection was performed with polyethyleneimine (PEI, 60 μg per dish) 
in a ratio of 3:1 with plasmid DNA (20 μg per dish). The PEI and plasmid DNA 
were incubated in serum-free medium (2 ml per dish) at room temperature for 
15 min, followed by dropwise addition to the cells. Transfection with the empty 
pcDNA3.1 vector was used to generate mock control samples. The medium was 
refreshed after 24 h and cells were collected after 48 or 72 h in cold PBS. Cells were 
centrifuged (10 min, 200g, 4 °C) and the supernatant was removed. The cell pellets 
were flash frozen in liquid N2 and stored at −80 °C.
Cell lysate preparation. Cell pellets were resuspended in lysis buffer: 20 mM 
HEPES, 2 mM DTT, 0.25 M sucrose, 1 mM MgCl2, 2.5 U ml−1 benzonase and 
incubated 30 min on ice. The cytosolic fraction (supernatant) was separated 
from the membranes by ultracentrifugation (30 min, 100,000g, 4 °C). The pellet 
was resuspended in storage buffer comprising 20 mM HEPES and 2 mM DTT 
(membrane fraction). All samples were stored at −80 °C. Protein concentrations 
were determined using a Bradford assay (Bio-Rad).
Mouse brain lysate preparation. Mouse brains were thawed on ice, dounce 
homogenized in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM DTT, 1 mM MgCl2, 
2.5 U ml−1 benzonase) and incubated on ice for (30 min). The membrane and 
cytosolic fractions of cell or tissue lysates were separated by ultracentrifugation 
(45 min, 100,000g, 4 °C). The supernatant was collected (cytosolic fraction) and the 
membrane pellet was resuspended in cold storage buffer (20 mM HEPES pH 7.2, 
2 mM DTT) by thorough pipetting and passage through a 1-ml insulin needle. 
Protein concentrations were determined using a Bradford assay (Bio-Rad). All 
samples were stored at −80 °C.
Western blot. Cell lysates were denatured with 4× Laemmli buffer (stock 
concentrations: 240 mM Tris-HCl pH 6.8, 8% w/v SDS, 40% v/v glycerol, 5% v/v 
β-mercaptoethanol, 0.04% v/v bromophenol blue, 30 min, room temperature) 
and 10–20 μg per sample was resolved on a 10% acrylamide SDS–PAGE gel 
(180 V, 75 min). Proteins were transferred from the gel to a 0.2-μm polyvinylidene 
difluoride membrane using a Trans-Blot Turbo (Bio-Rad). The membranes 
were washed with tris-buffered saline (TBS) (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl) and blocked with 5% milk in TBS and Tween 20 (TBST) (50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.05% Tween 20) 1 h at room temperature or overnight at 
4 °C. Primary antibodies against NAPE-PLD (Abcam, ab95397, 1:200, in TBST), 
FLAG-tagged proteins (Sigma Aldrich, F3165, 1:5,000 in 5% milk in TBST), 
α-tubulin (Genetex, GTX76511, 1:5,000 in 5% milk in TBST) or β-actin (Abcam, 
ab8226, 1:5,000 in 5% milk in TBST) were incubated 1 h at room temperature 
or overnight at 4 °C. Membranes were washed with TBST and incubated with 
secondary antibodies: for NAPE-PLD, goat-antirabbit-HRP (Santa Cruz, sc-
2030, 1:2,000 in 5% milk in TBST); for FLAG-tagged proteins and β-actin, 
goat-antimouse-HRP (Santa Cruz, sc-2005, 1:5,000 in 5% milk in TBST); for 
α-tubulin, goat-antirat (Santa Cruz, sc-2032, 1:5,000 in 5% milk in TBST). All 
secondary antibodies were incubated 1 h at room temperature or overnight at 
4 °C. Membranes were washed with TBST and TBS. The blot was developed in the 
dark using a luminol solution (10 ml, 1.4 mM luminol in Tris-HCl pH 7.5), ECL 
enhancer (100 μl, 6.7 mM para-hydroxycoumaric acid in DMSO) and H2O2 (3 μl, 
30% w/w in H2O). Chemiluminescence was visualized using a ChemiDoc Imaging 
System (Bio-Rad). Band intensity is normalized to α-tubulin or β-actin using 
ImageLab software (Bio-Rad).
qPCR. RNA isolation and cDNA synthesis was conducted as follows: total RNA 
from Neuro-2a cells was extracted using Trizol reagent (ThermoFisher Scientific). 
Once isolated, RNA concentration and purity were determined by Nanodrop 
(Denovix Inc.). Subsequently, cDNA synthesis was carried out with Maxima H 
minus first strand cDNA synthesis kit (ThermoFisher Scientific) according to the 
manufacturer’s instructions.
qPCR analysis was conducted as follows: 10 ng of input cDNA was analyzed 
using SybrGreen qPCR master mix (Biotool) in combination with CFX96 optical 
thermal cycler (Bio-Rad). Data analysis was performed using CFX Manager 
software (Bio-Rad). Data are expressed in quantitation cycles (Cq) and standard 
deviation of three technical replicates.
Activity assays. Surrogate substrate-based fluorescence assay NAPE-PLD. The 
NAPE-PLD activity assay was based on a previously reported method with small 
alterations20. The membrane fraction from transient overexpression of human 
or mouse NAPE-PLD in HEK293T cells was diluted to 0.4 μg μl−1 in assay buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.02% v/v Triton X-100). The substrate 
PED6 (Invitrogen, D23739) 1 mM stock in DMSO was consecutively diluted in 
DMSO (10×) and in assay buffer (10×) to make a 10 μM working solution. Relevant 
concentrations of compound (100× working solution) were prepared in DMSO. 
The assay was performed in a black Greiner 96-well plate (flat bottom), final volume 
100 μl. The compound or DMSO was incubated with membrane protein lysate 
(final concentration 0.04 μg μl−1) for 30 min at 37 °C. Then, substrate PED6 was 
added (final concentration 1 μM) and the measurement was started immediately 
on a TECAN infinite M1000 pro at 37 °C (excitation, 485 nm; emission, 535 nm; 
gain, 100), scanning every 2 min for 1 h. Mock membrane lysate with DMSO 
was used for background subtraction. The slope of t = 4 min to t = 14 min was 
used as the enzymatic rate (relative fluorescence units (RFU per min), which was 
normalized to DMSO as 100%. IC50 curves were generated using Graphpad Prism 
v.6 (log (inhibitor) versus normalized response with variable slope). Ki values 
were calculated from the Cheng–Prusoff equation Ki = IC50/(1 + ((S)/KM)) where 
S = [substrate] and KM = 0.59 μM for both mouse and human NAPE-PLD. All 
measurements were performed in n = 4 or n = 8 for controls, with Z’ ≥ 0.6.
HTS of NAPE-PLD activity assay. Details of the HTS of the NAPE-PLD activity 
assay are listed in Supplementary Table 1.
LC–MS-based endogenous NAPE-PLD activity assay. The NAPE-PLD assay to 
measure endogenous enzyme activity was performed as reported previously 
with small alterations using the synthetic substrate 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-heptadecanoyl (C17:0-NAPE (19), for preparation see 
Supplementary Notes)21. Mouse brain membrane lysates from male and female 
WT or NAPE-PLD KO mice (Virginia Polytechnic Institute and State University) 
were used originally generated by Leung et al.13. In an Eppendorf tube, per sample 
10 μg of mouse brain membrane lysate (5 mg ml−1) was diluted in assay buffer 
(50 mM Tris-HCl pH 7.5 + 0.1% Triton X-100) to a final volume of 47 μl. As a 
negative control, a sample was denatured at 100 °C for 10 min and cooled to room 
temperature for 5 min. LEI-401 (0.5 μl, 100× in DMSO) or DMSO was added 
and incubated for 30 min at room temperature. C17:0-NAPE (10 mM stock in 
9:1 CHCl3:MeOH) was diluted in EtOH to 10 μM and then added (2.5 μl, 20×, 
0.5 μM final concentration). The samples were incubated at 37 °C for 15 min. Next, 
10 μl internal standard OEA-d4 (100 nM) was added, followed by 50 μl NH4OAc 
buffer (0.1 M, pH 4) and 500 μl MTBE. The samples were vortexed using a Bullet 
Blender (4 min, Next Advance Inc.) and centrifuged for 11 min at 16,000g at 
4 °C. Then, 475 ml of the supernatant was transferred to a new Eppendorf tube 
and evaporated to dryness. Reconstitution in 200 μl acetonitrile, vortex (3 min) 
and centrifugation (13,000g, 2 min). Following that, 50 μl was transferred to 
an LC–MS vial with a micro insert. Next, 5 μl was injected in the LC–MS/MS 
system. A targeted analysis of C17:0 NAE was measured using an Acquity UPLC 
I class binary solvent manager pump in conjugation with a Xevo-TQ-S tandem 
quadrupole mass spectrometer (Waters Corporation). Separation of C17:0-NAE 
and OEA-d4 (internal standard) was performed with an Acquity HSS-T3 column 
(2.1 × 100 mm2, 1.8 μm particle size; Waters Corporation) maintained at 45 °C. The 
aqueous mobile phase A consisted of 2 mM ammonium formate and 10 mM formic 
acid, and the organic mobile phase B was acetonitrile. The flow rate was set to 
0.6 ml min−1; initial gradient conditions were 70% B held for 0.50 min and linearly 
ramped to 100% B over 1.5 min and held for 1 min; after 10 s the system returned 
to initial conditions and held for 2 min before the next injection. Electrospray 
ionization–MS was operated in positive mode for measurement of C17:0-NAE, and 
a selective multiple reaction mode was used for quantification. Data were analyzed 
with MassLynx v.4.1 software (Waters Corporation).
Natural substrate-based fluorescence assay DAGLα. The natural substrate assay 
for human and mouse DAGLα was performed as reported previously51. All 
measurements were performed in n = 4 or n = 8 for controls, with Z’ ≥ 0.6.
Surrogate substrate-based fluorescence assay DAGLβ. The biochemical mDAGLβ 
assay was performed as reported previously52. All measurements were performed in 
n = 4 or n = 8 for controls, with Z’ ≥ 0.6.
Natural substrate-based fluorescence assay MAGL. The natural substrate assay for 
human MAGL was performed as reported previously53. All measurements were 
performed in n = 4 or n = 8 for controls, with Z’ ≥ 0.6.
Radioligand displacement assays CB1 and CB2 receptor. [3H]CP55940 displacement 
assays to determine the affinity for the cannabinoid CB1 and CB2 were performed 
as previously described54.
Activity-based protein profiling (ABPP) for FAAH, ABHD6, ABHD12 and PLA2G4E 
activity. Gel-based ABPP was performed as previously described52. In brief,  
mouse brain membrane proteome or hPLA2G4E overexpressing membrane lysate 
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(9.5 μl and 2 μg μl−1 or 19.5 μl and 1 μg μl−1, respectively) was pre-incubated with 
vehicle or inhibitor (0.5 μl 20× or 0.5 μl 40× inhibitor stock in DMSO, respectively, 
30 min, room temperature) followed by incubation with the activity-based probe 
MB064 (250 nM, 0.5 μl 20× stock in DMSO) or FP-TAMRA (500 nM, 0.5 μl 20× 
stock in DMSO) for mouse brain lysate (15 min, room temperature) or FP-TAMRA 
(50 nM, 0.5 μl 40× stock in DMSO) for PLA2G4E overexpressing lysate (5 min, 
room temperature). Final concentrations for the inhibitors are indicated in the main 
text and figure legends. Proteins were denatured with 4× Laemmli buffer (3.5 μl, 
stock concentrations: 240 mM Tris-HCl pH 6.8, 8% w/v SDS, 40% v/v glycerol, 5% 
v/v β-mercaptoethanol, 0.04% v/v bromophenol blue, 30 min, room temperature). 
The samples (10 μl per slot) were resolved by SDS–PAGE (respectively, 10 or 8% 
acrylamide for mouse brain or PLA2G4E lysate, 180 V, 75 min). Gels were scanned 
using Cy3 and Cy5 multichannel settings (605/50 and 695/55 filters, respectively) 
on a ChemiDoc Imaging System (Bio-Rad). Fluorescence was normalized to 
Coomassie staining and quantified with ImageLab (Bio-Rad).
Generation of Neuro-2a NAPE-PLD KO populations. Single-guide RNA (sgRNA) 
selection. Two sgRNAs, located in exon 2 and 3 with high efficiency and specificity 
as predicted by CHOPCHOP v.2 online web tool (http://chopchop.cbu.uib.no)  
were selected. Guides were cloned into the BbsI restriction site of plasmid 
px330-U6-Chimeric_BB-CBh-hSpCas9 (gift from F. Zhang, Addgene plasmid 
no. 42230). The sgRNA targeting exon 3 yielded higher knockout efficiency as 
determined by western blot and in the T7E1-assays. This population was used for 
further experiments.
Sequential transfection. Neuro-2a cells were transfected sequentially (three times 
within the course of 10 d) to yield populations with a high knockout efficiency. 
Cells were seeded at day 0, day 3 and day 6 and transfected at day 1, day 4 and day 
7. Samples for T7E1 assays were collected at day 2, day 5, day 11 and after several 
weeks of culturing the cells.
One day before the first transfection, Neuro-2a cells were seeded to a six-well 
plate to reach 80–90% confluence at the time of transfection. Before transfection, 
culture medium was aspirated and 2 ml of fresh medium was added. A 5:1 
(m/m) mixture of PEI (17.5 μg per well) and plasmid DNA (3.5 μg per well) was 
prepared in serum-free culture medium (250 μl each) and incubated (15 min, 
room temperature). Transfection was performed by dropwise addition of the PEI/
DNA mixture to the cells. Then, 24 h posttransfection, the culture medium was 
refreshed, a small number of cells were collected for analysis by T7E1 assay and 
ABPP while the remainder was kept in culture under standard conditions for 
following transfections. After three transfection rounds, the cells were cultured 
according to standard protocol.
T7E1 assay. Genomic DNA was obtained by mixing 50 μl QuickExtract (Epicentre) 
with cell pellet (~10% of a well, from a six-well plate). The samples were incubated 
at 65 °C for 6 min, mixed by vortexing and then incubated at 98 °C for 2 min. 
Genomic DNA extracts were diluted in sterile water and directly used in PCR 
reactions. Genomic PCR reactions were performed on 2.5–5 μl isolated genomic 
DNA extract using Phusion High-Fidelity DNA Polymerase (ThermoFisher) in 
Phusion HF buffer in a final volume of 20 μl, for primers see Supplementary Table 7.
For the T7E1 assay, genomic PCR products were denatured and reannealed 
in a thermocycler using the following program: 5 min at 95 °C, 95 to 85 °C using 
a ramp rate of −2 °C s−1, 85–25 °C using a ramp rate of −0.2 °C s−1. To annealed 
PCR product (8.5 μl) was added NEB2 buffer (1 μl) and T7 endonuclease I 
(5 U, 0.5 μl; New England Biolabs), followed by incubation at 37 °C for 30 min. 
Digested PCR products were analyzed using agarose gel electrophoresis with 
ethidium bromide staining.
Agarose gels were analyzed using ImageLab Software (Bio-Rad) and CRISPR 
gene editing efficiency was expressed as percentage T7E cleavage (volume integral 
of digested bands/volume integral all bands × 100%).
Live cell photoaffinity labeling. Gel-based photoaffinity labeling. Here, 500,000 
HEK293T cells per well were seeded in a 12-well plate 1 d before transfection. On 
the day of transfection, the medium was refreshed with 0.375 ml medium per well. 
Transfection was performed with PEI (3 μg per well) and human NAPEPLD-FLAG 
or mock pcDNA3.1Neo plasmids (1 μg per well). PEI and plasmids were combined 
in serum-free medium (0.125 ml per well) and incubated for 15 min at room 
temperature, then added to each well. After 24 h the medium was refreshed. Then, 
48 h after transfection, the medium was removed and cells were washed with warm 
PBS (1×). This was followed by treatment with photoprobe 10 (1,000× in DMSO, 
final concentration: 2 μM) together with vehicle or competitor (600× in DMSO) in 
medium + serum (0.30 ml per well) for 30 min at 37 °C. The medium was aspirated 
and the cells were covered with PBS (0.15 ml per well), followed by 350 nm UV 
irradiation using a Caprobox at 4 °C for 10 min. The cells were collected into 
1.5 ml epps with cold PBS and centrifuged for 10 min at 2,000 r.p.m. at 4 °C. 
The PBS was removed and the cells were flash frozen with liquid N2 (cells can 
optionally be stored at −80 °C). The cells were lysed with lysis buffer (30 μl, 20 mM 
HEPES pH 7.2, 0.25 M sucrose, 1 mM MgCl2, benzonase 25 U ml−1) followed by 
pipetting up and down and incubating for 30 min on ice. Protein concentrations 
were measured using a Bradford assay (Bio-Rad), and cell lysates were diluted to 
2 μg μl−1 with lysis buffer. Next, 18 μg cell lysate (9 μl) was then clicked with Cy5-N3 
(for molecular structure see Supplementary Fig. 2) using a click mix (1 μl per 
sample, final concentrations: 1 mM CuSO4, 6 mM sodium ascorbate, 0.2 mM tris
(3-hydroxypropyltriazolylmethyl)amine (THPTA), 2 μM Cy5-N3) for 1 h at room 
temperature (note that it is important to separately prepare the click mix first with 
CuSO4 and sodium ascorbate, until a yellow color change is observed). Samples 
were denatured with 4× Laemmli buffer (3.33 μl, stock concentrations: 240 mM 
Tris-HCl pH 6.8, 8% w/v SDS, 40% v/v glycerol, 5% v/v β-mercaptoethanol,  
0.04% v/v bromophenol blue) and incubated for 30 min at room temperature.  
The samples were resolved by SDS–PAGE (10% acrylamide gel) at 180 V for 75 min, 
after which the gels were imaged at Cy3 and Cy5 channels (605/50 and 695/55 
filters, respectively) on a ChemiDoc Imaging System (Bio-Rad). Fluorescence is 
normalized to Coomassie or α-tubulin by western blot using ImageLab software 
(Bio-Rad). IC50 curves were generated using Graphpad Prism v.6.
Chemical proteomics-based photoaffinity labeling. Here, 2 × 106 HEK293T cells 
per well were seeded in a six-well plate 1 d before transfection. On the day 
of transfection, the medium was removed and refreshed with 1.125 ml fresh 
medium per well. Transfection was performed with PEI (9 μg per well) and 
human NAPEPLD-FLAG or mock pcDNA3.1Neo plasmids (3 μg per well). PEI 
and plasmids were combined in serum-free medium (0.375 ml per well) and 
incubated for 15 min at room temperature, then added to each well. After 24 h the 
medium was refreshed. Next, 48 h after transfection, the medium was removed 
and cells were washed with warm PBS (1×). This was followed by treatment 
with photoprobe 10 (1,000× in DMSO, final concentration of 2 μM) together 
with vehicle or competitor (1,000× in DMSO, final concentration 20 μM) in 
medium + serum (1 ml per well) for 30 min at 37 °C. The medium was aspirated 
and the cells were covered with PBS (0.5 ml per well), followed by 350 nm UV 
irradiation using a Caprobox at 4 °C for 10 min. The cells were collected into 
1.5-ml epps with cold PBS and centrifuged for 10 min at 2,000 r.p.m. at 4 °C. 
The PBS was removed and the cells were flash frozen with liquid N2 (cells can 
optionally be stored at −80 °C). The cells were lysed with lysis buffer (30 μl, 20 mM 
HEPES pH 7.2, 0.25 M sucrose, 1 mM MgCl2, benzonase 25 U ml−1) followed by 
pipetting up and down and incubating for 30 min on ice. Protein concentrations 
were measured using a Bradford assay (Bio-Rad), and cell lysates were diluted to 
1 μg μl−1 with lysis buffer.
From here the label-free chemical proteomics protocol was followed 
as previously described30. Then, 270 μg cell lysate (270 μl) was clicked with 
biotin-N3 (Sigma Aldrich, 762024) using a click mix (30 μl per sample, 
final concentrations: 1 mM CuSO4, 6 mM sodium ascorbate, 0.2 mM tris
(3-hydroxypropyltriazolylmethyl)amine (THPTA), 4 μM biotin-N3) for 1 h at 
room temperature (note that it is important to separately prepare the click mix 
first with CuSO4 and sodium ascorbate, until a yellow color change is observed). 
Proteins were precipitated using chloroform (166 μl), methanol (666 μl) and MilliQ 
(366 μl H2O). Samples were centrifuged for 10 min at 1,500g and the solvents were 
carefully removed. Methanol (600 μl) was added and the protein were resuspended 
using a probe sonicator (30% amplitude, 10 s). After centrifugation (5 min, 18,400g) 
the solvent was removed and the samples were resuspended again in urea buffer 
(250 μl, 6 M urea, 250 mM NH4HCO3) by pipetting up and down. DTT (2.5 μl, final 
concentration 10 mM) was added and the samples were incubated at 65 °C with 
shaking (600 r.p.m.) for 15 min. After cooling to room temperature, iodoacetamide 
(20 μl, final concentration 40 mM) was added and incubated in the dark at 20 °C 
with shaking (600 r.p.m.) for 30 min. Next, SDS (70 μl, 10%) was added and 
incubated at 65 °C with shaking (600 r.p.m.) for 5 min. For 18 samples, 1.8 ml of 
avidin agarose beads (Thermo Scientific, 20219) were divided over three 15 ml 
tubes and washed with PBS (3 × 10 ml2). The beads in each tube were resuspended 
in PBS (6 ml) and divided over 18 tubes (1 ml each). To each tube was added the 
denatured sample and PBS (2 ml) and the tubes were rotated with an overhead 
shaker at room temperature for 3 h. After centrifugation (2 min, 2,500g) and 
removal of the supernatant, the beads were consecutively washed with 0.5% SDS 
in PBS (w/v, 6 ml) and PBS (3 × 6 ml2), each time centrifuging (2 min, 2,500g). The 
beads were transferred to a 1.5-ml low binding epp (Sarstedt, 72.706.600) with 
on-bead digestion buffer (250 l, 100 mM Tris pH 8.0, 100 mM NaCl, 1 mM CaCl2, 
2% v/v acetonitrile) and to each sample was added 1 μl trypsin solution (0.5 μg μl−1 
trypsin (Promega, V5111), 0.1 mM HCl). Proteins were digested at 37 °C with 
shaking (950 r.p.m.) overnight. Formic acid (12.5 μl) was added to each sample 
and the beads were filtered off using a biospin column (Bio-Rad, 7326204), the 
flow-through was collected in a 2-ml epp. Samples were purified using StageTips. 
Each StageTip was conditioned with MeOH (50 μl, centrifugation: 2 min, 300g), 
followed by StageTip solution B (50 μl, 80% v/v acetonitrile, 0.5% v/v formic acid in 
MilliQ, centrifugation for 2 min, 300g) and StageTip solution A (50 μl, 0.5% v/v  
formic acid in MilliQ, centrifugation for 2 min, 300g). Next, the samples were 
loaded, centrifuged (2 min, 600g) and the peptides on the StageTip were washed 
with StageTip solution A (100 μl, centrifugation for 2 min, 600g). The StageTips 
were transferred to a new 1.5 ml low binding epp and the peptides were eluted 
with StageTip solution B (100 μl, centrifugation for 2 min, 600g). The solvents were 
evaporated to dryness in a SpeedVac concentrator at 45 °C for 3 h. Samples were 
reconstituted in LC–MS solution (50 μl, 3% v/v acetonitrile, 0.1% v/v formic acid, 
1 μM yeast enolase peptide digest (Waters, 186002325) in MilliQ).
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The peptides were measured as described previously for the NanoACQUITY 
UPLC System coupled to SYNAPT G2-Si high definition mass spectrometer30. 
A trap-elute protocol, where 5 μl of the digest was loaded on a trap column 
(C18 100 Å, 5 μM, 180 μM × 20 mm, Waters) followed by elution and separation 
on the analytical column (HSS-T3 C18 1.8 μM, 75 μM × 250 mm, Waters). The 
sample was brought onto this column at a flow rate of 10 μl min−1 with 99.5% 
solvent A for 2 min before switching to the analytical column. Peptide separation 
was achieved using a multistep concave gradient based on gradients previously 
described30. The column was re-equilibrated to initial conditions after washing 
with 90% solvent B. The rear seals of the pump were flushed every 30 min with 
10% (v/v) acetonitrile. [Glu1]-fibrinopeptide B (GluFib) was used as a lock mass 
compound. The auxiliary pump of the LC system was used to deliver this peptide 
to the reference sprayer (0.2 μl min−1). A UDMSe method was set up as previously 
described30. Briefly, the mass range was set from 50 to 2,000 Da with a scan time 
of 0.6 s in positive, resolution mode. The collision energy was set to 4 V in the 
trap cell for low-energy MS mode. For the elevated energy scan, the transfer 
cell collision energy was ramped using drift-time specific collision energies. 
The lock mass was sampled every 30 s. For raw data processing, PLGS (v.3.0.3) 
was used. The MSE identification workflow was performed with the parameters 
summarized in Supplementary Table 7 to search the human proteome from 
Uniprot (uniprot-homo-sapiens-trypsin-reviewed-2016_08_29.fasta). Protein 
quantification was performed using ISOQuant (v.1.5). The parameter settings used 
are summarized in Supplementary Table 7.
Data analysis. Protein targets of photoprobe 10 were selected based on the 
following cut-offs: (1) ≥2-fold enrichment for UV-treated versus non-UV-treated 
samples; (2) unique peptides ≥2; (3) testing for significance using Student’s t-test 
(unpaired, two-tailed), P < 0.05 was considered significant and (4) Benjamini–
Hochberg correction with a false discovery rate (FDR) of 10%.
Targeted lipidomics in Neuro-2a cells. The targeted lipidomics experiments were 
based on previously reported methods with small alterations55.
Sample preparation. Here, 2 × 106 Neuro-2a cells (grown at 37 °C, 7% CO2) were 
seeded 1 d before treatment in 6 cm dishes. Before treatment, cells were washed 
twice with warm PBS and then treated with vehicle or compound (10 μM, 0.1% 
DMSO) in 3 ml medium without serum (2 h at 37 °C, n = 5 per condition). 
Washing with cold PBS (1×) followed by gathering in 1.5 ml Eppendorf tubes and 
centrifugation (10 min, 1,500 r.p.m.). PBS was removed and the cell pellets were 
flash frozen with liquid nitrogen and stored at −80 °C. Live cell count with trypan 
blue was performed after compound treatment to test for cell viability. Next, 10% 
of each cell sample (collected during gathering) was used to determine the protein 
concentration using a Bradford assay (Bio-Rad) for normalization after lipid 
measurements.
Statistical analysis. Absolute values of lipid levels were corrected using the 
measured protein concentrations. Data were tested for significance with GraphPad 
v.6 using one-way analysis of variance (ANOVA) with Tukey correction for 
multiple comparisons. P < 0.05 was considered significant.
In vitro ADME profile. Kinetic aqueous solubility (lyophilization solubility assay). 
The solubility of LEI-401 in phosphate buffer at pH 6.5 from an evaporated 
10 mM DMSO compound stock solution was measured. Two aliquots of the 
test compound were dried and dissolved in phosphate buffer at pH 6.5. The 
solutions were then filtered and diluted (three different dilution levels for each 
compound) before RapidFire MS analysis was performed. Each test compound 
was quantified using a six-point calibration curve prepared with the same DMSO 
starting solution.
Passive membrane permeability through PAMPA. PAMPA is a method that 
determines the permeability of substances from a donor compartment, through 
a lipid-infused artificial membrane into an acceptor compartment. Read-out 
is a permeation coefficient Peff drug as well as test compound concentrations 
in donor, membrane and acceptor compartments. The assay was performed as 
described elsewhere54.
Microsomal clearance. The microsomal clearance assay was performed as 
previously described54. Pooled commercially available microsome preparations 
from male mouse microsomes (C57BL/6J, Lot 4339006) were purchased from 
Corning Inc.). For human, ultrapooled liver microsomes (150 mixed gender 
donors, BD UltraPool HLM 150, Lot 38289) were purchased to account for 
the biological variance in vivo from human liver tissues. For the microsome 
incubations (incubation buffer 0.1 M phosphate buffer pH 7.4), 96-deep well 
plates were applied, which were incubated at 37 °C on a TECAN (Tecan Group 
Ltd) equipped with Te-Shake shakers and a warming device (Tecan Group Ltd). 
The reduced nicotinamide adenine dinucleotide phosphate regenerating system 
consisted of 30 mM glucose-6-phosphate disodium salt hydrate; 10 mM NADP; 
30 mM MgCl2 × 6H2O and 5 μg μl−1 glucose-6-phosphate dehydrogenase (Roche 
Diagnostics) in 0.1 M potassium phosphate buffer pH 7.4. Incubations of LEI-401 
at 1 μM in microsome incubations of 0.5 μg μl−1 plus cofactor reduced nicotinamide 
adenine dinucleotide phosphate were performed in 96-well plates at 37 °C. After 
1, 3, 6, 9, 15, 25, 35 and 45 min 40 μl incubation solutions were transferred and 
quenched with 3:1 (v/v) acetonitrile containing internal standards. Samples were 
then cooled and centrifuged before analysis by LC–MS/MS. The log peak area 
ratios (test compound peak area/internal standard peak area) were plotted against 
incubation time using a linear fit. The calculated slope was used to determine the 
intrinsic clearance: CLint (μl min−1 mg−1 protein) = −slope (min−1) × 1,000/(protein 
concentration (μg μl−1)).
Hepatocyte clearance. The hepatocyte clearance assay was performed as 
previously described54. For animals, hepatocyte suspension cultures were either 
freshly prepared by liver perfusion studies or prepared from cryopreserved 
hepatocyte batches (pooled C57BL6 mouse hepatocytes were purchased from 
BioreclamationIVT). For human, commercially available, pooled (5–20 donors), 
cryopreserved human hepatocytes from nontransplantable liver tissues were used. 
For the suspension cultures, Nunc U96 PP-0.5 ml (Nunc Natural, 267245) plates 
were used, which were incubated in a Thermo Forma incubator from Fischer 
Scientific equipped with shakers from Variomag Teleshake shakers (Sterico) 
for maintaining cell dispersion. The cell culture medium was William’s media 
supplemented with Glutamine, antibiotics, insulin, dexamethasone and 10% FCS. 
Incubations of a test compound at 1 μM test concentration in suspension cultures 
of 1 × 106 cells per ml (~1 μg μl−1 protein concentration) were performed in 96-well 
plates and shaken at 900 r.p.m. for up to 2 h in a 5% CO2 atmosphere at 37 °C. After 
3, 6, 10, 20, 40, 60 and 120 min 100 μl cell suspension in each well was quenched 
with 200 μl methanol containing an internal standard. Samples were then cooled 
and centrifuged before analysis by LC–MS/MS. The log peak area ratios (test 
compound peak area/internal standard peak area) or concentrations were plotted 
against incubation time with a linear fit. The slope of the fit was used to calculate 
the intrinsic clearance: CLint (μl min−1/1 × 106 cells) = −slope (min−1) × 1,000/
(1 × 106 cells).
Plasma protein binding. The plasma protein binding assay was performed as 
previously described54. Pooled and frozen plasma from human (HMPLEDTA, lot 
BRH1060627) and mouse (MSEPLEDTA3-C57, lot MSE196204) were obtained 
from BioreclamationIVT. The Teflon equilibrium dialysis plate (96-well, 150 μl, 
half-cell capacity) and cellulose membranes (12–14 kDa molecular weight 
cut-off) were purchased from HT-Dialysis (Gales Ferry). Both biological matrix 
and phosphate buffer pH were adjusted to 7.4 on the day of the experiment. 
The determination of unbound compound was performed using a 96-well 
format equilibrium dialysis device with a molecular weight cut-off membrane of 
12–14 kDa. The equilibrium dialysis device itself was made of Teflon to minimize 
nonspecific binding of the test substance. Compounds were tested in cassettes of 
2–5 with an initial total concentration of 1,000 nM, one of the cassette compounds 
being the positive control diazepam. Equal volumes of matrix samples containing 
substances and blank dialysis buffer (Soerensen buffer at pH 7.4) were loaded into 
the opposite compartments of each well. The dialysis block was sealed and kept 
for 5 h at a temperature of 37 °C and 5% CO2 environment in an incubator. After 
this time, equilibrium has been reached for most small molecule compounds with 
a molecular weight of <600. The seal was then removed and matrix and buffer 
from each dialysis was prepared for analysis by LC–MS/MS. All protein binding 
determinations were performed in triplicate. The integrity of membranes was 
tested in the HT-Dialysis device by determining the unbound fraction values for 
the positive control diazepam in each well. At equilibrium, the unbound drug 
concentration in the biological matrix compartment of the equilibrium dialysis 
apparatus was the same as the concentration of the compound in the buffer 
compartment. Thus, the percentage unbound fraction (fu) was calculated by 
determining the compound concentrations in the buffer and matrix compartments 
after dialysis as follows: %fu = 100 × buffer concentration after dialysis/matrix 
concentration after dialysis. The device recovery was checked by measuring 
the compound concentrations in the matrix before dialysis and calculating the 
percent recovery (mass balance). The recovery must be within 80–120% for data 
acceptance.
P-glycoprotein active efflux assay. P-glycoprotein (permeability-glycoprotein, 
abbreviated to ‘P-gp’ and also known as multidrug resistance protein 1 (MDR1)) is 
the most-studied and best-characterized drug transporter. The P-gp assay evaluates 
the ability of test compounds to serve as a P-gp substrate. The assay was performed 
as described elsewhere54.
logD-assay. For the determination of the octanol/water distribution coefficient 
(logD), the carrier-mediated distribution system-assay was used as described 
elsewhere54.
In vivo pharmacokinetics and lipidomics. Subjects. Male C57BL/6J mice (Jackson 
Laboratory) or male and female NAPE-PLD KO mice originally from a mixed 
129SvJ-C57BL/6J background (Virginia Polytechnic Institute and State University) 
generated by Leung et al.13 served as subjects for the in vivo pharmacokinetic 
and brain lipid analysis of LEI-401. Animal protocols were approved by 
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the Institutional Animal Care and Use Committee at National Institute on 
Alcohol Abuse and Alcoholism, National Institute of Health, the Bundesamt 
für Lebensmittelsicherheit und Veterinärwesen (BLV) der Schweizerischen 
Eidgenossenschaft, the Dierexperimentencommissie Universiteit Leiden and by 
the Institutional Animal Care and Use Committee at Virginia Commonwealth 
University in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals56. All studies involving animals are reported 
in accordance with the Animal Research: Reporting of In Vivo Experiments 
guidelines for reporting experiments involving animals57.
Pharmacokinetic analysis of LEI-401 (mouse plasma). Test compounds were 
formulated according to respective protocols either by dissolution (intravenous, 
i.v.) or in a glass potter until homogeneity was achieved (oral (p.o.) and i.p.). 
Formulations were injected i.v. using a 30G needle in the lateral tail vein mice 
yielding a 1 mg kg−1 dose. For p.o. applications, animals were gavaged (yielding a 
10 mg kg−1 dose) and for i.p. applications the compounds were injected into the 
abdomen (yielding a 30 mg kg−1 dose). At the following time points blood was 
drawn into EDTA: 0.083, 0.25, 0.5, 1, 2, 4, 7 and 24 h (for p.o. and i.p. the first time 
point was omitted). Three animals each were used for the i.v. and p.o. arm and 
six animals were used in the i.p. arm. Animals were distributed randomly over 
the time course and at each time point, a volume of 100 μl of blood was taken. 
Quantitative plasma measurement of the compound was performed by LC–MS/
MS analysis. Pharmacokinetic analysis was conducted using Phoenix WinNonlin 
v.6.4 software using a noncompartmental approach consistent with the route 
of administration. For assessment of the exposure Cmax, Tmax, area under curve 
and bioavailability were determined from the plasma concentration profiles. 
Parameters (CL, Vss, t1/2) were estimated using nominal sampling times relative to 
the start of each administration.
Pharmacokinetic analysis of LEI-401 (mouse brain). Mice were injected with LEI-
401 (30 mg kg−1, i.p., single dose) dissolved in sterile DMSO (D2650 Sigma) and 
mixed with Tween-80 and distilled H2O at a ratio of 1:1:8. Mice were killed after 1, 
2, 4 and 8 h. Brain samples were rapidly collected, washed in ice cold saline, blotted 
dry, frozen in liquid N2 and stored at −80 °C until further analysis. Brain levels of 
LEI-401 were quantified by LC–MS/MS using an Agilent 6410 triple quadrupole 
mass spectrometer (Agilent Technologies) coupled with an Agilent 1200 LC system 
(Agilent Technologies). Chromatographic and mass spectrometer conditions 
were set as described previously58. Chromatographic separation was obtained 
using 2.5-μl samples injected onto a Zorbax SB-C18 rapid resolution HT column 
(2.1 × 50 mm2, 1.8 μm, Agilent). The mass spectrometer was set for electrospray 
ionization in positive ion mode. The source parameters were as follows: capillary 
voltage, 4,000 V; gas temperature, 350 °C; drying gas, 10 l min−1; nitrogen was used 
as the nebulizing gas with a pressure of 40 psig. Collision-induced dissociation 
energy was performed by using nitrogen. Levels of LEI-401 were analyzed by 
multiple reactions monitoring. Mass spectrometric conditions were optimized for 
LEI-401 with injection of synthetic standard by using MassHunter Workstation 
Optimizer software (Agilent Technologies). The molecular ion and fragments 
for LEI-401 measured were as follows: m/z 422.26 → 70.1 and 422.26 → 137 
(collision-induced dissociation energy, 56 and 40 V, respectively). The amounts 
of LEI-401 in the samples were determined against standard curves. Values are 
expressed as ng g−1 in wet brain tissue weight.
Lipid measurements in mouse brain. Levels of NAEs, 2-AG and arachidonic acid 
were measured by stable isotope dilution LC–MS/MS as described previously59.
In vitro ABPP of LEI-401-treated mice. Male C57BL/6J mice were treated with 
LEI-401 (30 mg kg−1, i.p., single dose) or vehicle (DMSO, Tween-80 and distilled 
H2O; 1:1:8) and killed after 2 h by cervical dislocation. Brain samples were rapidly 
collected, frozen in liquid N2 and stored at −80 °C until further analysis. After 
membrane lysate preparation (vide supra), 19.5 μl lysate (2 mg ml−1) per sample 
was treated with 0.5 μl probe (40× stock in DMSO, final concentration 250 nM for 
MB064, 500 nM for fluorescence polarization-boron dipyrromethene (BODIPY) 
(1 μM for DH379) and incubated for 15 min at room temperature or 30 min at 
37 °C for DH379. Proteins were denatured with 4× Laemmli buffer (7.5 μl, stock 
concentrations: 240 mM Tris-HCl pH 6.8, 8% w/v SDS, 40% v/v glycerol, 5% v/v 
β-mercaptoethanol, 0.04% v/v bromophenol blue, 30 min, room temperature). 
From the DH379-labeled samples 10 µl (14 µg protein) of quenched reaction 
mixture was resolved on 10% acrylamide SDS–PAGE (180 V, 75 min). The MB064- 
and FP-BODIPY-labeled samples were combined (1:1 v/v) and resolved together  
on 10% acrylamide SDS–PAGE (180 V, 75 min). Fluorescence was measured using 
a Bio-Rad ChemiDoc MP system (fluorescence channel filters BODIPY, Cy2  
(460–490 nm); BODIPY-TMR dye, Cy3 (520–545 nm); protein ladder, Cy5  
(625–650 nm)). Gels were then stained using Coomassie staining and imaged 
for protein loading control. Fluorescence quantification was performed using 
ImageLab (Bio-Rad). Intensities were normalized to the DMSO control and 
corrected for protein loading by Coomassie staining.
Statistical analysis. Data were tested for significance with GraphPad v.6 using 
one-way ANOVA with Dunnett’s correction for multiple comparisons. Two-way 
ANOVA was used to evaluate LEI-401 versus vehicle in NAPE-PLD KO versus WT 
mice. P < 0.05 was considered significant.
HPA axis activation. Pharmacological treatment and c-Fos labeling. All drugs were 
dissolved in 5% DMSO, 5% Tween-80, and 90% saline the day of each experiment. 
The CB1 antagonist AM251 (3 mg kg−1; Cayman Chemical), FAAH inhibitor 
URB597 (1 mg kg−1; Cayman Chemical) and the NAPE-PLD inhibitor LEI-410 
(30 mg kg−1) were administered intraperitoneally (i.p., 10 ml kg−1).
All animals (C57BL/6J mice) received 4 d of handling before test days. On test 
day, animals received drug injections 105 (AM251/vehicle) and 210 min (URB597/
LEI-410/vehicle) before perfusions. Animals were deeply anesthetized using 
pentobarbital injection and perfused intracardially with 4% paraformaldehyde and 
PBS. After perfusion, the brains were extracted and fixed in 4% paraformaldehyde 
at 4 °C overnight and then submerged in 30% sucrose in PBS at 4 °C for 48 h. 
Using a mouse brain atlas, brains were mounted with optimal cutting temperature 
compound and sectioned (40 μm) on a cryostat. Slices containing the PVN were 
placed in PBS until antibody treatment.
Sections were washed three times (10 min per wash) in a PBS and 0.1% Triton 
X-100 (PBST) solution before incubation in PBS blocking buffer containing 10% 
normal donkey serum at room temperature for 1 h. Sections were incubated in 
primary antibody rabbit anti-c-Fos (1:300 Cell Signaling) at 4 °C overnight. Tissue 
was then washed in PBST solution three more times (10 min each) and then 
incubated in donkey antirabbit Cy3 (1:100 JacksonImmuno) at room temperature 
for 2 h. Sections were washed in PBST three more times, then mounted in PBS 
and examined using a Leica fluorescent microscope. Two slices containing the 
PVN were collected from each specimen. Grayscale images were taken of both 
hemispheres separately for each slice. All images within experiments were obtained 
under the same exposure and magnification (20×). Images were processed on 
ImageJ, where they were subjected to a brightness threshold before c-Fos labeled 
cells were counted based on size criteria set for each experiment. Number of 
labeled cells inside a defined region (24,614.47 μm2) that met the set criteria  
were measured and the density of c-Fos expressing cells was compared across  
drug groups.
CORT measurements. To measure circulating CORT levels, tail blood was taken 
45 (AM251/vehicle) and 150 min (URB597/LEI-410/vehicle) after injections. 
Blood samples were centrifuged at 3,000 r.p.m. for 20 min at 4 °C. Serum was 
stored at −80 °C until analysis with an enzyme-linked immunosorbent assay kit 
(Arbor Assays) by following the manufacturer’s instructions. Samples were tested 
in triplicate and diluted 1:1,000 to make sure levels fitted into the standard curve. 
Values were normalized to the control (vehicle) group of each experiment.
Behavioral testing. Subjects. Subjects were male 7–12-week-old C57BL/6J mice 
obtained from The Jackson Laboratory. Mice were housed two per cage in a 
temperature- and humidity-controlled vivarium under a 12 h light/dark cycle 
(lights on 6:00 h). Experimental procedures were performed in accordance with the 
National Institutes of Health Guide for Care and Use of Laboratory Animals and 
approved by the local Animal Care and Use Committee. The number of mice used 
in each experiment is indicated in the figure legends. Before testing, each mouse 
was handled for 2 min per day for 5 d. Mice were acclimated in a room next to test 
area 1 h before the experiment.
Fear conditioning. Fear conditioning was conducted in ‘context A’: a 30 × 25 ×  
21 cm3 operant chamber (Med Associates, Inc.) with metal walls and a metal rod 
floor. To provide an additional olfactory cue, the chamber was cleaned between 
subjects with a 79.5% water: 19.5% ethanol: 1% vanilla extract solution. After 
a 180-s stimulus-free context acclimation, there were three lots of pairings of a 
30-s, 75-dB white noise cue (conditioned stimulus) and a 2-s 0.6-mA scrambled 
coterminating footshock (unconditioned stimulus). Between each stimulus was 
an increasing interpairing interval (60–90–120 s). Following the last pairing 
was a 120-s stimulus-free period. Stimulus presentation waps controlled by 
the Med Associates VideoFreeze system (Med Associates). Freezing (no visible 
movement except respiration) was scored every 5 s by an observer blind to 
condition/treatment and converted to a percentage ((freezing observations/total 
observations) × 100).
Fear extinction training. Fear extinction training occurred the following day 
in ‘context B’: a 27 × 27 × 14 cm3 operant chamber with transparent walls and a 
floor covered with wood chips, cleaned between subjects with a 99% water: 1% 
acetic acid solution and housed in a different room from training. One hour 
and fourty-five minutes before extinction, mice were injected with one of four 
combinations of drug intervention (see the section Pharmacological treatments). 
After a 180-s stimulus-free baseline, there were 50 × 30-s conditioned stimulus 
presentations (5-s interconditioned stimulus interval).
Extinction retrieval. Extinction retrieval was tested 1 d and 10 d after extinction 
training in context B, via 5 × 30-s conditioned stimulus presentations (5-s 
interconditioned stimulus interval) beginning after a 180-s stimulus-free baseline. 
The mean number of freezing observations per baseline period and 5× conditioned 
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stimulus block was converted to a percentage ((number of freezing observations/
total number of observations per period) × 100) for analysis.
Statistical analysis. The effects of treatment and trial-block on freezing during 
extinction training were analyzed using two-way ANOVA, with repeated measures 
for a trial block. The effect of drug treatment on freezing during retrieval was 
analyzed using ANOVA.
Pharmacological treatments. Pre-extinction treatment of NAPE-PLD inhibitor 
LEI-401 (30 mg kg−1, i.p.), FAAH inhibitor AM3506 (1 mg kg−1, i.p.) and their 
vehicle controls were administered 1 h 45 min before the extinction training 
in two consecutive injections. Every injection combination led to four groups: 
vehicle + vehicle, vehicle + AM3506, vehicle + LEI-401 and AM3506 + LEI-
401. LEI-401 stock (30 mg ml−1) was prepared in DMSO. Aliquots of LEI-401 
were mixed with Tween-80 and sterile distilled H2O (1:1:8) and AM3506 stock 
(10 mg ml−1) was prepared in DMSO and mixed with saline (1:9) just before 
administration (in a volume of 10 ml kg−1) before extinction training.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article 
(and its Supplementary Information files) or are available from the corresponding 
author on reasonable request. The mass spectrometry proteomics data (raw data and 
ISOQuant output tables for proteins groups and peptides) have been deposited in 
the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) 
via the PRIDE partner repository with the dataset identifier PXD017586.
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